Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31383662 | 0.87 | DGAT2 (0.41) | ESR2RORCNR1H2MAPK1DGAT2 | |
| SCHEMBL31383588 | 0.83 | GRM5 (0.40) | USP30ESR2GRM5GRM1TRPV3 | |
| SCHEMBL25119907 | 0.82 | GRM1 (0.54) | GRM5GRM1 | |
| SCHEMBL31383654 | 0.80 | MAPK1 (0.43) | ESR2GRM5GRM1RORCNR1H2 | |
| SCHEMBL30919924 | 0.79 | DGAT2 (0.39) | ESR2GRM5GRM1RORCDGAT2 | |
| SCHEMBL31287970 | 0.78 | MKNK1 (0.36) | ESR2GRM5GRM1RORCNR1H2 | |
| SCHEMBL19458937 | 0.78 | GPR119 (0.41) | USP30ESR2NR1H2MAPK1DGAT2 | |
| SCHEMBL31383681 | 0.78 | KCNH2 (0.39) | USP30ESR2GRM5GRM1NR1H2 | |
| SCHEMBL31357911 | 0.78 | MAPK1 (0.39) | ESR2GRM5GRM1NR1H2MAPK1 | |
| SCHEMBL31287995 | 0.77 | DGAT2 (0.36) | ESR2GRM5GRM1RORCNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | NEURO3 THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025029897-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | NEURO3 THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | QDPR, DPYD, P2RX4 | USP30 4060/4885ESR2 3321/4885GRM5 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.